Methods. Among 32 strains described in a previous clinical study, we focused on the most 29 antibiotic-tolerant strains including coagulase-negative staphylococci (n=4), Staphylococcus 30 aureus (n=4), Enterococcus faecalis (n=2), Pseudomonas aeruginosa (n=4) and 31
Enterobacteriaceae (n=4). We used in vitro biofilm model (96-well plate assay) to study 32 biofilm tolerance and we tested various combinations of antibiotics and non-antibiotic 33 adjuvants. Gentamicin, amikacin or vancomycin were combined with disodium EDTA or L-34 arginine during 24 hours, to reproduce the Antibiotic Lock Therapy (ALT) approach. 35
Mortality of biofilm bacteria was measured by cfu quantification after a vigorous step of 36 pipetting up and down in order to detach all biofilm bacteria from the surface of the wells. 37
Results. Both of our adjuvant strategies significantly increased the effect of antibiotics 38 against biofilms formed by Gram-positive and Gram-negative bacterial pathogens. The 39 combination of gentamicin + EDTA was active against all tested strain but one P. aeruginosa. 40
The combination of gentamicin + L-arginine was active against most of tested strains with the 41 notable exception of coagulase-negative staphylococci for which no potentiation was 42 observed. We also demonstrated that combination using amikacin + EDTA was active against 43
Gram-negative bacteria and vancomycin + EDTA against Gram-positive bacteria.
Introduction

49
Following an initial report in 1988 1 , several studies demonstrated that antibiotic lock therapy 50 (ALT) could be a therapeutic option in case of catheter-related bloodstream infection 51 (CRBSI). [1] [2] [3] ALT relies on the instillation of a small volume of highly concentrated antibiotic 52 solution that dwells in the lumen of the catheter for 12 to 72 hours, in order to eradicate 53 biofilm formed on the inner surface of the device. 1, 4 Indeed, most of treatment difficulties 54 encountered during CRBSI are related to the presence of high cell density bacterial 55 communities called bacterial biofilms. 5 Biofilms display characteristic properties, including 56 high tolerance towards antimicrobials that is defined by the ability of a subset of bacteria to 57 survive in the presence of high concentration of antibiotics. 6, 7 58 Recent IDSA guidelines recommend that ALT should be used in case of conservative 59 treatment of uncomplicated long-term intravenous catheter-related bloodstream infections 60 caused by coagulase-negative staphylococci or Enterobacteriaceae. 8 This statement is based 61 on different studies reporting salvage rates ranging from 80 to 90% in these situations. 4 
62
However, other groups reported higher failure rates, even in case of coagulase-negative 63 staphylococci infections. 9, 10 Furthermore, infections caused by Staphylococcus aureus or 64
Pseudomonas aeruginosa are still considered to be at higher risk of treatment failure, despite 65 recent encouraging results, for the latter case. 4, 11 Lastly, ALT requires locking the long-term 66 intravenous catheter and thus reduces it's availability for 7 to 14 days. Thus, there is a dire 67 need for more efficient locks in order to improve biofilm eradication and reduce the time 68 during which the catheter is unavailable. 69
We previously demonstrated that 2 adjuvant strategies could be used to eradicate in 70 vivo biofilms formed by various Gram-positive as well as Gram-negative nosocomial 71 pathogens. 12, 13 The first strategy relies on the use of EDTA, a cation chelator that destabilizes 72 the biofilm matrix.
14 EDTA has been shown to increase the effect of gentamicin against invitro biofilms but also to reduce the risk of CRBSI, when associated with minocycline. 12, 17 We also recently demonstrated that increasing the pH of a 78 gentamicin-based lock solution with the clinically compatible alkaline amino-acid L-arginine 79 led to the eradication of biofilms formed by S. aureus and E. coli. 13 Indeed, alkaline pH 80 increased the effect of aminoglycosides against planktonic as well as biofilm persister cells, 81 both in vitro and in vivo. 13 While these results were obtained with laboratory strains, we 82 wondered whether these approaches could also be effective against a wide range of clinical 83 strains responsible for CRBSI. Using clinical strains collected during a previously published 84 prospective study, our main objective was to test in vitro the spectrum of action of the 85 combination of gentamicin and EDTA or L-arginine. 18 We also studied other combinations 86 including antibiotics that are commonly used in case of CRBSI caused by gentamicin-87 resistant strains, such as vancomycin or amikacin. 4, 19, 20 88
Materials and methods
90
Bacterial strains and growth conditions. Between February 2009 and October 2010, we 91 conducted a prospective study in Beaujon Hospital, a tertiary teaching hospital, during which 92 72 patients were included with a diagnosis of TIVAP-related infection. 18 Bacterial strains 93 were collected and stored at -80°C. For the present study, we decided to focus on patients 94 included with a diagnosis of TIVAP-related BSI, i.e. the most relevant clinical indication for 95 ALT (Supplementary Figure 1) . 4, 8 We identified 43 cases of TIVAP-related BSI diagnosed 96
at Beaujon and restricted our study to the most frequent bacterial pathogens responsible for 97 CRBSI: Enterobacteriaceae, coagulase-negative staphylococci, S. aureus, P. aeruginosa and 98
Enterococcus faecalis.
18 Among our strains, some did not resume growth when bacterial 99 stocks were streaked on blood agar plates. As a result, we recovered 32 strains that have been 100 further studied ( Table 1) . 101
Gram-positive bacteria (S. aureus, coagulase-negative staphylococci, E. faecalis) were grown 102 in tryptic soy broth (TSB) supplemented with 0.25% (or 0.5% for E. faecalis) glucose (TSB 103 glucose). Gram-negative bacteria (P. aeruginosa and Enterobacteriaceae) were grown in 104 Lysogeny Broth (LB). 21 Unless specified, all chemicals and antibiotics were purchased from 105 Sigma-Aldrich (St. Louis, MO). EDTA was prepared as follow. Briefly, 0.5M stock solution 106 of disodium EDTA was prepared in water. Then, NaOH was added dropwise in order to reach 107 a pH of ~8. EDTA was used at the final concentration of 30 mg/mL. 108
109
Determination of minimal inhibitory concentration Minimal inhibitory concentrations 110
(MIC) were determined by broth microdilution in cation-adjusted Mueller-Hinton broth, as 111 recommended by the Clinical and Laboratory Standards Institute (CLSI). 22, 23 Stationary phase 112 cultures were diluted 1:100 in fresh media and cultured at 37°C with agitation until reaching 113 exponential growth. Then, bacterial inoculum was standardized up to a final concentration of 114 5.10 5 cfu/mL and exposed to serially diluted concentrations of antibiotics. Gentamicin and 115 vancomycin were tested for Gram-positive bacteria. Gentamicin and amikacin were tested for 116
Gram-negative bacteria. MIC was defined as the first well with no visible bacterial growth. 117
The final value was the mean of 3 independent experiments. We used CLSI thresholds to 118 define if a strain was susceptible or resistant towards one of the tested antibiotics ( Table 1) . 23 
120
In vitro biofilm formation. In vitro biofilms were grown in triplicate for 24 hours (S. aureus, 121 S. epidermidis, E. faecalis and Enterobacteriaceae) or 48 hours (P. aeruginosa) on UV-122 sterilized polyvinyl chloride (PVC) 96-well plates (Thermo Scientific, Rochester, NY), as 123 previously described. 13, 24 Briefly, stationary phase cultures were diluted up to OD 600nm of 0.05 124 in fresh media and 100µL of this inoculum was used in each well. Gram-positive bacterial 125 biofilms were grown in TSB supplemented with 0.25% (or 0.5% for E. faecalis) glucose. 126
Gram-negative bacterial biofilms were grown in LB broth. After 24 hours (or 48 hours for P. 127 aeruginosa), planktonic bacteria were removed by 1X PBS washing and biofilms treated for 128 24 hours using different lock solutions (see below). After 24 hours, each well was washed 129 twice with 1X PBS to remove planktonic bacteria and excess antibiotics and surviving cfu 130 were quantified with a vigorous step of pipetting up and down in order to detach all biofilm 131 bacteria from the surface of the wells. cfu were compared to 24h biofilms and expressed as % 132 of survival. 13, 24 For S. aureus, coagulase-negative staphylococci and Enterobacteriaceae, we 133 decided to retain only the 4 most tolerant strains (i.e. the strains with the highest percentage of 134 bacterial survival) after a 24-h exposure to the bactericidal antibiotic gentamicin at 5 mg/mL, 135 a concentration that is usually recommended as ALT (Supplementary Figure 2) . 8 
Results
151
EDTA-gentamicin lock is active against most tested clinical strains. 152
We first compared the activity of gentamicin alone or GEN+EDTA locks against in vitro 153 biofilm formed in microtiter plate assay by clinical strains responsible for CRBSI.
We 154 observed that all tested strains exhibited various degrees of tolerance towards antibiotics with 155 0.01 to 50% of bacterial survival after a 24-h exposure to 5 mg/mL of gentamicin. Among the 156 18 tested clinical strains, all but one P. aeruginosa strain exhibited a significant reduction of 157 bacterial survival when disodium EDTA was added to gentamicin (Figure 1 to 5) . The effect 158 was also seen against highly tolerant strains, i.e. strains with high % of survival when exposed 159 to high concentration of gentamicin alone. For instance, even if 50% of S. epidermidis strain 160 50 biofilm bacteria survived after gentamicin challenge, the adjunction of EDTA increased 161 bacterial mortality by 3-log (Figure 2A) . Similar findings were made with highly tolerant 162 strains of S. aureus (Figure 1A) , E. faecalis ( Figure 3A) , P. aeruginosa ( Figure 4D ) and 163 Enterobacteriaceae (Figure 5A and D) . Lastly, the effect could also be seen against resistant 164 strains, such as P. aeruginosa strain 32. 165
Taken together, these results demonstrate that the adjunction of disodium EDTA significantly 166 increases the effect of gentamicin against biofilms formed by almost all tested strains of 167 bacterial pathogens responsible for CRBSI, including highly tolerant or resistant bacteria. 168
169
The combination of L-arginine and gentamicin is active against all tested pathogens but 170
S. epidermidis. 171 Against S. aureus, E. faecalis, Enterobacteriaceae and P. aeruginosa, GEN+L-arg lock is 172
active against almost all tested strains, with the exception of one strain of K. pneumoniae 173 (Figure 1, 3, 4 and 5) . Conversely, the adjunction of L-arginine to gentamicin did not 174 increase the effect of antibiotic alone against S. epidermidis (Figure 2) . Against S. aureus orsurvival comparing GEN+EDTA and GEN+L-arg locks (Figure 1 and 4) . 177
Taken together, these results demonstrate that even if GEN+L-arg lock is active against S. 178 aureus, E. faecalis, Enterobacteriaceae and P. aeruginosa, it does not significantly increase 179 the effect of gentamicin against coagulase-negative staphylococci. 180
181
Use of EDTA also increases the efficiency of alternative antibiotic locks. 182
We then tested the effect of vancomycin or amikacin alone or associated with EDTA against 183 our array of clinical strains to compare their activity on antibiotic resistant or susceptible 184 bacteria. 19, 20 We focused our study on EDTA, as it exhibited the wider spectrum of action. 185 Against S. aureus or E. faecalis, gentamicin was associated with higher mortality of biofilm 186 bacteria, as compared with vancomycin in all tested strains but 1 S. aureus (Figure 1 and 3) . 187
Conversely, against S. epidermidis, vancomycin was more active than gentamicin in 2 strains, 188 less active in 1 strain and equally active in 1 strain (Figure 2) . Against Gram-positive 189 bacteria, the adjunction of EDTA increased mortality of biofilm bacteria, in all cases ( Figure  190   1 to 3) . However, in the case of S. aureus, the effect was related only to the effect of EDTA 191 alone, as demonstrated by the absence of a significant difference between EDTA and 192 VAN+EDTA (Figure 1) . Conversely, against coagulase-negative staphylococci and E. 193 faecalis, VAN+EDTA was more active than EDTA alone (Figure 2 and 3) . Gram-negative pathogens suggests that these locks could be successfully used in clinical 205 situations. 12, 13 However, these adjuvant strategies were only tested on a limited number of 206 laboratory bacterial strains and testing the efficiency of these locks against a wide and 207 clinically relevant panel of strains responsible for CRBSI constitutes a mandatory preliminary 208 towards potential clinical study. Here, we tested these 2 adjuvant strategies combining EDTA 209 or L-arginine with aminoglycosides against 18 strains collected during a prospective study, 210 specifically designed to study the clinical outcome after CRBSI. 18 We demonstrated that the 211 adjuvant gentamicin + EDTA strategy was effective on a broader spectrum of Gram-positive 212 and Gram-negative bacterial pathogens as compared to the adjuvant gentamicin + L-arginine 213 strategy. Additionally, we showed that efficiency of other aminoglycosides such as amikacin 214 (in Gram-negative bacteria) and vancomycin (in Gram-positive bacteria) are also potentiated 215 by EDTA adjunction. 216
More specifically, we observed that the adjunction of EDTA significantly increases the effect 217 of gentamicin against all tested strains but one P. aeruginosa. However, in this later strain, we 218 also observed a trend toward a higher activity when GEN+EDTA was compared to 219 gentamicin alone (p=0.073). We previously demonstrated that GEN+EDTA used as ALT was 220 amenable to clinical studies as it eradicated biofilms formed by bacterial nosocomial 221 pathogens. 12 Furthermore, another group also reported that GEN+EDTA was a promising 222 combination for biofilm eradication. 15 The potentiation of gentamicin effect is very likely due 223 to the ability of cation chelator to destabilize the biofilm matrix or because of a direct 224 bactericidal effect of EDTA against biofilm bacteria.
14, 25 In the present study, the fact that we 225 do not reach biofilm eradication during in vitro experiments is very likely due to the short 226 course of lock treatment (24 hours), as compared to in vivo experiments (at least 5 days), as 227 well as the presence of the immune system in vivo that may favor clearance of biofilm 228 bacteria when weakened by the treatment. To date, no in vitro, in vivo or clinical data support 229 the use of ALT during only one day. So far, a possible limitation for the use of EDTA is its 230 commercial availability that is restricted to its association with minocycline. 231
We also tested another strategy using L-arginine as an adjuvant to gentamicin in order 232 to increase bacterial persisters' mortality within biofilms. 13 Whereas L-arginine efficiently 233
increased gentamicin activity against most tested bacteria, we did not observe any gentamicin 234 potentiation against S. epidermidis. As S. epidermidis is a frequent pathogen in case of 235 CRBSI, this limitation is important and should be taken into account before considering any 236 clinical studies. One possible explanation regarding this observation is the frequent carriage 237 of ACME (arginine catabolic mobile element) by coagulase-negative staphylococci. ACME 238 frequently includes arc, a gene cluster encoding a complete additional arginine deiminase 239 pathway. 26 ,27 ACME is found in more than 65% of methicillin-susceptible or resistant S. 240 epidermidis strains. 26, 28 Hence, one can hypothesize that, in S. epidermidis, increased arginine 241 metabolism could reduce its adjuvant effect. Indeed, ACME is less frequently found in S. 242 aureus, as compared with coagulase-negative staphylococci. 26, 29 
243
We also observed an important variability between different strains within a single 244 species regarding the effects of antibiotics alone or the magnitude of the synergistic effect. 245
This observation highlights the importance of testing any candidate compound or combination 246 against multiple strains representative of each bacterial species to rule out any strain-specific 247 effect. 248
Three percents of methicillin-susceptible S. aureus and 11% of methicillin-resistant S. 249 aureus were found to be gentamicin-resistant in a recent survey of hospital-acquired 250 infections in Texas. 19 In Canadian intensive care units, 8% of E. coli and 32% of P. 251 aeruginosa were gentamicin-resistant. 20 More strikingly, 60% of S. epidermidis responsible 252 for bloodstream infections in Germany were gentamicin-resistant. 30 Thus, identifying the 253 most active approach against gentamicin-resistant bacteria is essential. In vivo, we previously 254
showed that a 5-day GEN+EDTA ALT procedure allows the eradication of biofilm formed by 255 gentamicin-resistant S. aureus. 12 Here, we also noticed that a synergistic effect could be seen 256 Few studies compared the activity of gentamicin to other drugs against biofilms using 272 a standardized method. Against S. epidermidis and S. aureus, it has been shown that 273 vancomycin was more active that gentamicin in biofilm setting. 31, 32 However, in vivo, 274 gentamicin at 40 mg/mL was shown to be more active that vancomycin at 2 mg/mL against S. 275 aureus. 33 In the present study, gentamicin was more active than vancomycin against S. aureus 276 or E. faecalis biofilms. The results were less clear-cut in the case of S. epidermidis, since 277 vancomycin was more active than gentamicin in 2 strains, less active in 1 strain and equally 278 active in 1 strain. Against Gram-negative bacteria, amikacin was as active as gentamicin in 5 279 out of 8 strains but more active than gentamicin in the remaining 3 strains. However, no other 280 in vitro or in vivo study compared the activity of gentamicin to amikacin as locks against 281
Gram-negative bacteria. 282
To note, the characteristics of the surface that is used for biofilm formation might 283 influence the phenotype of tolerance towards antibiotics. In our case, the surface of the 96- 
